Prostate cancer (PC) remains a leading cause of cancer-related morbidity in men worldwide.
Emerging evidence suggests that the brain-type creatine kinase isoenzyme (CK-BB) is overexpressed in PC tissue and correlates with tumor progression.
However, conventional assays for CK-BB lack the sensitivity and rapid turnaround required for routine clinical use.
